Technology Bundle ID: TAB-2201

Compounds That Treat Malaria and Prevent Malaria Transmission

Request More Info
Licensing Contact:
Primary Inventors: 
Xin-zhuan Su (NIAID)
Co-Inventors: 
Dipak Raj (NIAID), Jing Yuan (NIAID), Ronald Johnson (NCATS), Ruili Huang (NCATS), Sittiporn Pattaradilokrat (NIAID)
Institute or Center: 
NCATS, NIAID

Malaria is the single leading cause of death, especially among children, in the developing world. Malaria is caused by infection with parasites of the genus Plasmodium, transmitted by mosquitos. In addition to transmission, vital steps in the parasite lifecycle occur in the mosquito host. The invention offered for licensing relates to therapeutic compounds and related pharmaceutical compositions that can be used in the prevention and treatment of malaria infection. More specifically, the invention is drawn to compounds that may kill sexual and mosquito stage malaria parasites to block transmission. Specifically claimed is the antihistamine Ketotifen, which has demonstrated activity blocking parasite development in mosquitoes. Also claimed are treatments encompassing Ketotifen with other existing antimalarial drugs in a combination treatment aimed at multiple stages in the malaria life cycle.

Applications:
  • Prevention and treatment of malaria infections.
Advantages:
  • Drugs that kill sexual and mosquito stages of the parasite are important for preventing and/or slowing the spread of malaria infection and ultimately for malaria eradication.
  • Primaquine, the only currently available drug shown to block transmission, is known to cause serious adverse side effects.

Patents

PCT Application PCT/US2010/047019
Filed on 2010-08-27
US Application 15/192,779
Filed on 2016-06-24
US Application 61/237,417
Filed on 2009-08-27
US Pat 9,375,424

Issued 2016-06-28

Various international patent applications may also be available.

Publications

Eastman RT, et al.
PMID 23129054

License Status

Available for licensing.

Updated

Jul 18, 2017

Data Source: 
tts